Base- The viremic prevalence is estimated to peak in 2019 at 8.9 million (M) infections while decompensated and compensated LC peak in 2031 at 163,000 and 1.2 M cases, respectively. DAA- a 3% decrease in HCC and liver-related (LR) mortality was observed, although no change in viremic prevalence or compensated LC was found. Prevention- the number of new infections is modeled to decrease to 81,900 by 2023, and chronic HCV prevalence to decrease by 1.64

million cases, from 2014 – 2030. Little to no change in LR mortality or HCC was found under this scenario. Prevention+DAA- a 20% reduction in prevalence was maintained, with an additional 8% decrease in HCC and LR mortality. Conclusions: Under the current standard of care, advanced selleck compound library liver disease and LR mortality will increase, despite decreasing prevalence. In the absence of treatment or higher SVR therapies, prevention of HCV decreased overall prevalence, but did not impact short term LR mortality or HCC.

A dual approach reducing incidence and increasing treatment did, however, show short term improvements in advanced stage outcomes with reductions in prevalence. Table: Modeled HCV burden, 2014 and 2030, India *Base: current rates of new cases and treatment with Peg+Riba Disclosures: Sarah Blach – Employment: Center for Disease Analysis Ashish Kumar – Consulting: Abbott, Ranbaxy Homie Razavi – Management Position: Center for Disease Analysis The following people have nothing to disclose: Pankaj Puri, Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya, Shiv K. Sarin, Radha K. Dhiman, Rakesh Aggarwal, Shivaram P. Singh, Deepak N. Amarapurkar, GSK126 molecular weight Anil Arora, Mohinish Chhabra, Kamal Chetri, Gourdas Choudhuri, Abhijit Chowdhury, Vinod K. Dixit, Ajay K. Duseja, Ajay K. Jain, Dharmesh Kapoor, Premashis

Kar, Abraham Koshy, Kaushal selleck inhibitor Madan, Sri P. Misra, Mohan V. Prasad, Aabha Nagral, Amarendra S. Puri, Jeyamani Ramachandran, Sanjiv Saigal, Samir R. Shah, Praveen K. Sharma, Ajit Sood, Sandeep Thareja, Manav Wadhawan Purpose: Patients who have failed one regimen of Hepatitis C (HCV) treatment are often candidates for a second course using newer agents. Therefore the purpose of this study was to characterize treatment failure rates with triple therapy consisting of peg-interferon alpha and ribavirin in combination with either boceprevir or telaprevir and identify factors associated with failure. Methods: We conducted a retrospective cohort study of HCV patients, treated with triple therapy, in Kaiser Permanente Southern California. Adult patients (≥ 18 years) diagnosed with HCV and having positive HCV-RNA titers were identified through their electronic medical record. Patients had to initiate and complete therapy between May 1, 2011 and December 31, 2012, and were also required to be continuously enrolled with a drug benefit during the six months prior to treatment initiation. Data were collected on patient demographics, baseline health status and comorbid conditions.